EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management

Morie A Gertz iD

American Journal of Hematology · 2025-06 · 100 (6) · 1061-1073

DOI: 10.1002/ajh.27666 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 17.03.2025. Verfasst von Morie A Gertz. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease Overview Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma with immunoglobulin M (IgM) monoclonal protein. Clinical features include anemia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, and rarely hyperviscosity. Diagnosis The presence of IgM monoclonal protein associated with ≥ 10% clonal lymphoplasmacytic cells in bone marrow confirms the diagnosis. The L265P mutation in MYD88 is detectable in more than 90% of patients and is found in most IgM MGUS patients. MYD88 is not required for the diagnosis. Risk Stratification Age, albumin, hemoglobin level, platelet count, β 2 microglobulin, Lactate dehydrogenase (LDH), and monoclonal IgM concentrations are characteristics that are predictive of outcomes. Risk‐Adapted Therapy Not all patients who fulfill WM criteria require therapy; these patients can be observed until symptoms develop. Rituximab‐monotherapy is inferior to combination regimens. Recommended first‐line therapy can be chemoimmunotherapy or a covalent Bruton tyrosine kinase inhibitor. The preferred Mayo Clinic induction is either rituximab and bendamustine (without rituximab maintenance) or zanubrutinib. Management of Refractory Disease Bortezomib, cyclophosphamide, fludarabine, thalidomide, everolimus, pirtobrutinib, carfilzomib, lenalidomide, bendamustine, and venetoclax have all been shown to have activity in relapsed WM. Given WM's natural history, the reduction of therapy toxicity is an important part of treatment selection. Most patients succumb to causes unrelated to macroglobulinemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaHumansRisk AssessmentImmunoglobulin MRituximabAntineoplastic Combined Chemotherapy ProtocolsMyeloid Differentiation Factor 88Disease Management

Stichwörter der Autor:innen

Waldenström macroglobulinemiachemotherapyhyperviscositylymphomamonoclonal gammopathyneuropathy

Substanzen

Immunoglobulin MRituximabMyeloid Differentiation Factor 88MYD88 protein, human

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Morie A Gertz

Zitieren

APA

Gertz, M. A. (2025). Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management. American Journal of Hematology, 100(6), 1061-1073. https://doi.org/10.1002/ajh.27666

Vancouver

Gertz MA. Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management. American Journal of Hematology. 2025;100(6):1061-1073. doi:10.1002/ajh.27666

BibTeX
@article{Gertz2025,
  author = {Gertz, Morie A},
  title = {Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management},
  journal = {American Journal of Hematology},
  year = {2025},
  volume = {100},
  number = {6},
  pages = {1061--1073},
  doi = {10.1002/ajh.27666}
}
Kostenlos starten →